Follow the people · Insider

JB

Jean Jacques Bienaime

Insider · Director · KROS

Jean Jacques Bienaime files insider transactions with the SEC as a director of Keros Therapeutics (KROS). We hold 14 disclosed purchases and sales filed since 4 January 2006, 4 of them in the last 90 days.

  • Files forKROS
  • Disclosed buys and sells14 in all, 4 in the last 90 days
  • Last disclosure19 August 2026

Positions held

9 posts we hold — a term names its own dates; a run of filings only says when they filed
  • Filed 3 June 202417 August 2026Director · Keros Therapeutics (KROS)12 Form 4 lines · source: SEC Form 4
  • Filed 26 May 202614 August 2026Director · Ascendis Pharma A/S (ASND)7 Form 4 lines · source: SEC Form 4
  • Filed 7 November 202310 June 2026Director · Immunome (IMNM)19 Form 4 lines · source: SEC Form 4
  • Filed 20 January 20158 June 2026Director · Incyte (INCY)58 Form 4 lines · source: SEC Form 4
  • Filed 3 January 200620 May 2024Chief Executive Officer · Biomarin Pharmaceutical (BMRN)1,385 Form 4 lines · source: SEC Form 4
  • Filed 23 April 200124 September 2018Director · Vital Therapies (VTL)16 Form 4 lines · source: SEC Form 4
  • Filed 6 April 201229 September 2014Director · Intermune (ITMN)19 Form 4 lines · source: SEC Form 4
  • Filed 22 May 201316 May 2014Director · Portola Pharmaceuticals (PTLA)6 Form 4 lines · source: SEC Form 4
  • Filed 7 May 20077 February 2012Director · NeurogesX (NGSX)77 Form 4 lines · source: SEC Form 4

Everything they disclosed

120 entries, newest first — one per disclosure report, one per Form 4 line

Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.